Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Estimated likelihood ratios for predicting BRCA1 or BRCA2 mutation status defined by breast tumor triple-negative phenotype

From: Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

Gene Breast tumor phenotype Diagnosis <50 years Diagnosis ≥50 to 70 years
% Carriers % BCAC LR (95% CI) % Carriers % BCAC LR (95% CI)
BRCA1 Triple-negative 67.3 17.5 3.73 (3.43-4.05) 57.7 12.9 4.41 (3.86-5.04)
Not triple-negative 32.7 82.5 0.40 (0.37-0.44) 42.3 87.1 0.49 (0.42-0.56)
  100% 100%    100% 100%   
BRCA2 Triple-negative 13.0 17.5 0.72 (0.59-0.87) 23.5 12.9 1.79 (1.42-2.24)
Not triple-negative 87.0 82.5 1.06 (0.98-1.15) 76.5 87.1 0.88 (0.78-1.00)
  100% 100%    100% 100%   
  1. Analyses stratified by country, as described in the Methods section. Analysis included tumor phenotypes from 2,249 BRCA1 mutation carriers (1,788 < 50 years, 461 ≥ 50 years), 1,195 BRCA2 mutation carriers (859 < 50 years, 336 ≥ 50 years) and 19,178 BCAC cases with no report of positive BRCA1/2 mutation status (7,103 < 50 years, 12,075 ≥ 50 years). LR, likelihood ratio. Triple-negative phenotype defined as ER-negative, PR-negative, HER2-negative; not triple-negative; all other combinations, with status measured for all three markers.
Back to article page